{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T07:55:21Z","timestamp":1790668521683,"version":"4.1.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T00:00:00Z","timestamp":1789084800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T00:00:00Z","timestamp":1789084800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AAPS J"],"DOI":"10.1208\/s12248-026-01308-w","type":"journal-article","created":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T18:39:32Z","timestamp":1789151972000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Four decades of History &amp; Evolution of Clinical Pharmacology at US Food and Drug Administration (FDA)\u2013 Part I: Product Quality"],"prefix":"10.1208","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4973-3822","authenticated-orcid":false,"given":"Mehul","family":"Mehta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,11]]},"reference":[{"key":"1308_CR1","unstructured":"OCP-Annual-Report. OFFICE of CLINICAL PHARMACOLOGY 2025 Annual Report 2025. Available from: https:\/\/www.fda.gov\/media\/191717\/download?attachment."},{"key":"1308_CR2","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1023\/A:1015829422034","volume":"9","author":"VP Shah","year":"1992","unstructured":"Shah VP, Midha KK, Dighe S, McGilveray IJ, Skelly JP, Yacobi A, et al. Analytical methods validation: bioavailability, bioequivalence, and pharmacokinetic studies. Pharm Res. 1992;9:588\u201392.","journal-title":"Pharm Res"},{"key":"1308_CR3","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1023\/A:1007669411738","volume":"17","author":"VP Shah","year":"2000","unstructured":"Shah VP, Midha K, Findlay J, Hill HM, Husle JD, McGilveray IJ, et al. Bioanalytical Methods Validation: A Revisit With a Decade of Progress. Pharm Res. 2000;17:1551\u20137.","journal-title":"Pharm Res"},{"issue":"2","key":"1308_CR4","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1208\/s12248-014-9696-2","volume":"17","author":"B Booth","year":"2013","unstructured":"Booth B, Arnold ME, DeSilva B, Amaravadi L, Dudal S, Fluhler E, et al. Workshop report: Crystal City V--quantitative bioanalytical method validation and implementation: the 2013 revised FDA guidance. AAPS J. 2013;17(2):277\u201388.","journal-title":"AAPS J"},{"issue":"2","key":"1308_CR5","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1208\/s12248-009-9100-9","volume":"11","author":"DM Fast","year":"2009","unstructured":"Fast DM, Kelley M, Viswanathan CT, O\u2019Shaughnessy J, King SP, Chaudhary A, et al. Workshop report and follow-up--AAPS workshop on current topics in GLP bioanalysis: assay reproducibility for incurred samples--implications of Crystal City recommendations. AAPS J. 2009;11(2):238\u201341.","journal-title":"AAPS J"},{"issue":"10","key":"1308_CR6","doi-asserted-by":"publisher","first-page":"1962","DOI":"10.1007\/s11095-007-9291-7","volume":"24","author":"CT Viswanathan","year":"2007","unstructured":"Viswanathan CT, Bansal S, Booth B, DeStefano AJ, Rose MJ, Sailstad J, et al. Quantitative bioanalytical methods validation and implementation: best practices for chromatographic and ligand binding assays. Pharm Res. 2007;24(10):1962\u201373.","journal-title":"Pharm Res"},{"key":"1308_CR7","unstructured":"ICH-Guideline. M10 Bioanalytical Method Validation and Study Sample Analysis 2022. Available from: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/m10-bioanalytical-method-validation-and-study-sample-analysis."},{"issue":"6","key":"1308_CR8","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1007\/BF01068419","volume":"15","author":"DJ Schuirmann","year":"1987","unstructured":"Schuirmann DJ. A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. J Pharmacokinet Biopharm. 1987;15(6):657\u201380.","journal-title":"J Pharmacokinet Biopharm"},{"issue":"10","key":"1308_CR9","first-page":"S143","volume":"11","author":"L Augsburger","year":"1994","unstructured":"Augsburger L, Shangraw R, Lesko L, Williams R. An approach toward establishing a scientific foundation for interpreting regulations and workshop on scale-up and post approval changes. Pharm Res. 1994;11(10):S143.","journal-title":"Pharm Res"},{"key":"1308_CR10","unstructured":"FDA-Guidance-Document. SUPAC-IR: Immediate-Release Solid Oral Dosage Forms: Scale-Up and Post-Approval Changes: Chemistry, Manufacturing and Controls, In Vitro Dissolution Testing, and In Vivo Bioequivalence Documentation 1995. Available from: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/supac-ir-immediate-release-solid-oral-dosage-forms-scale-and-post-approval-changes-chemistry."},{"key":"1308_CR11","unstructured":"FDA-Guidance-Document. SUPAC-MR: Modified Release Solid Oral Dosage Forms Scale-Up and Postapproval Changes: Chemistry, Manufacturing, and Controls; In Vitro Dissolution Testing and In Vivo Bioequivalence Documentation 1997. Available from: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/supac-mr-modified-release-solid-oral-dosage-forms-scale-and-postapproval-changes-chemistry."},{"key":"1308_CR12","unstructured":"FDA-Guidance-Document. Guidance for Industry - Extended Release Oral Dosage Forms: Development, Evaluation, and Application of In Vitro\/In Vivo Correlations. 1997. Available from: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/extended-release-oral-dosage-forms-development-evaluation-and-application-vitroin-in-vivo-correlations."},{"key":"1308_CR13","unstructured":"ICH-Guideline. Q11 Development and Manufacture of Drug Substances (Chemical Entities and Biotechnological\/Biological Entities) 2012. Available from: https:\/\/database.ich.org\/sites\/default\/files\/Q11%20Guideline.pdf."},{"key":"1308_CR14","unstructured":"FDA-Guidance-Document. Bioequivalence Studies With Pharmacokinetic Endpoints for Drugs Submitted Under an Abbreviated New Drug Application 2021. Available from: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/bioequivalence-studies-pharmacokinetic-endpoints-drugs-submitted-under-abbreviated-new-drug."},{"key":"1308_CR15","unstructured":"FDA-Guidance-Document. Bioavailability Studies Submitted in NDAs or INDs \u2013 General Considerations 2022. Available from: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/bioavailability-studies-submitted-ndas-or-inds-general-considerations."},{"issue":"1","key":"1308_CR16","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1038\/clpt.1985.138","volume":"38","author":"A Karim","year":"1985","unstructured":"Karim A, Burns T, Wearley L, Streicher J, Palmer M. Food-induced changes in theophylline absorption from controlled-release formulations. Part I. Substantial increased and decreased absorption with Uniphyl tablets and Theo-Dur sprinkle. Clin Pharmacol Ther. 1985;38(1):77\u201383.","journal-title":"Clin Pharmacol Ther"},{"key":"1308_CR17","unstructured":"FDA-Guidance-Document. Assessing the Effects of Food on Drugs in INDs and NDAs \u2013 Clinical Pharmacology Considerations 2022. Available from: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/assessing-effects-food-drugs-inds-and-ndas-clinical-pharmacology-considerations."},{"issue":"3","key":"1308_CR18","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1002\/cpt.28","volume":"97","author":"LX Yu","year":"2015","unstructured":"Yu LX, Jiang W, Zhang X, Lionberger R, Makhlouf F, Schuirmann DJ, et al. Novel bioequivalence approach for narrow therapeutic index drugs. Clin Pharmacol Ther. 2015;97(3):286\u201391.","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"1308_CR19","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1002\/cpt.3460","volume":"117","author":"M Donnelly","year":"2025","unstructured":"Donnelly M, Fang L, Madabushi R, Zhu H, Luke M, Canterbury C, et al. Narrow therapeutic index drugs: FDA experience, views, and operations. Clin Pharmacol Ther. 2025;117(1):116\u201329.","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"1308_CR20","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1023\/A:1016212804288","volume":"12","author":"GL Amidon","year":"1995","unstructured":"Amidon GL, Lennern\u00e4s H, Shah VP, Crison JR. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res. 1995;12(3):413\u201320.","journal-title":"Pharm Res"},{"key":"1308_CR21","doi-asserted-by":"publisher","DOI":"10.1021\/acs.molpharmaceut.7b00687","author":"M Mehta","year":"2017","unstructured":"Mehta M, Uppoor R, Conner D, Seo P, Vaidyanathan J, Volpe D, et al. Impact of the US FDA \u201cbiopharmaceutics classification system\u201d (BCS) guidance on global drug development. Mol Pharm. 2017. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.7b00687.","journal-title":"Mol Pharm"},{"key":"1308_CR22","unstructured":"Guideline ES. ICH M9 on biopharmaceutics classification system based biowaivers - Scientific guideline 2020. Available from: https:\/\/www.ema.europa.eu\/en\/ich-m9-biopharmaceutics-classification-system-based-biowaivers-scientific-guideline."},{"key":"1308_CR23","unstructured":"FDA-Review. Ambien CR - NDA 21774 Clinical Pharmacology and Biopharmaceutics Reviews. 2005. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2005\/021774s000_BioPharmR.pdf."},{"issue":"4","key":"1308_CR24","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1002\/cpt.2174","volume":"110","author":"L Fang","year":"2021","unstructured":"Fang L, Uppoor R, Xu M, Sharan S, Zhu H, Tampal N, et al. Use of partial area under the curve in bioavailability or bioequivalence assessments: a regulatory perspective. Clin Pharmacol Ther. 2021;110(4):880\u20137.","journal-title":"Clin Pharmacol Ther"},{"key":"1308_CR25","unstructured":"FDA-Approval-Package. Drug Approval Package: TYRUKO 2023. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2023\/761322Orig1s000TOC.cfm."},{"key":"1308_CR26","unstructured":"FDA-Guidance-Document. Considerations in Demonstrating Interchangeability With a Reference Product: Update. FDA; 2024. Available from: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/considerations-demonstrating-interchangeability-reference-product-update."},{"issue":"10","key":"1308_CR27","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0292231","volume":"18","author":"TMAC Herndon","year":"2023","unstructured":"Herndon TMAC, Brahme NN, Schrieber SJ, Luo M, Andrada FC, et al. Safety outcomes when switching between biosimilars and reference biologics: a systematic review and meta-analysis. PLoS ONE. 2023;18(10):e0292231.","journal-title":"PLoS ONE"},{"key":"1308_CR28","unstructured":"FDA-Guidance-Document. Applications Covered by Section 505(b)(2). FDA; 1999. Available from: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/applications-covered-section-505b2."},{"key":"1308_CR29","unstructured":"OCP-FDA. Office of Clinical Pharmacology Web Page: FDA; 2026. Available from: https:\/\/www.fda.gov\/about-fda\/cder-offices-and-divisions\/office-clinical-pharmacology."}],"container-title":["The AAPS Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-026-01308-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1208\/s12248-026-01308-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-026-01308-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T07:03:19Z","timestamp":1790665399000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1208\/s12248-026-01308-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,11]]},"references-count":29,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["1308"],"URL":"https:\/\/doi.org\/10.1208\/s12248-026-01308-w","relation":{},"ISSN":["1550-7416"],"issn-type":[{"value":"1550-7416","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,11]]},"assertion":[{"value":"3 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"No conflicts of interest to report.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"145"}}